Taylor Wessing advises Innate Pharma S.A. on its recent in-licensing agreement with Cancer Research Technology Limited

13-Apr-2007  |  Corporate, Intellectual Property, Life Sciences & Healthcare, Technology

CLIENT

Innate Pharma SA

VALUE

Not disclosed

TRANSACTION

Collaboration and licensing deal

DESCRIPTION

Advised Innate Pharma S.A. on its recent in-licensing agreement with the Cancer Research Technology Limited. The agreement grants Innate Pharma exclusive and worldwide development and commercialisation rights to a panel of discovery stage novel toll-like receptor (TLR) agents